MedTrace Logo

Statins and Breast Cancer Biomarkers

NCT00914017 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2010-02-11

No results posted yet for this study

Summary

There is laboratory evidence that cholesterol lowering medications (statins) inhibit the growth of breast cancer cells. Clinical studies are controversial but some show that women taking statins are less likely to get breast cancer. This ongoing randomized trial compares one-year of atorvastatin (Lipitor™) or placebo for lowering mammography-defined breast density and other surrogate markers associated with breast cancer risk.

Conditions

Interventions

DRUG

Atorvastatin

Atorvastatin, 40 mg daily for 1 year

DRUG

Placebo

sugar pill daily for 1 year

Sponsors & Collaborators

  • Breast Cancer Research Foundation

    collaborator OTHER

  • Cancer and Leukemia Group B

    collaborator NETWORK

  • University of Vermont

    lead OTHER

Principal Investigators

  • Marie E Wood, MD · University of Vermont

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00914017 on ClinicalTrials.gov